Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Lifevantage (LFVN) Asset Writedowns and Impairment (2026)

Lifevantage filings provide 1 years of Asset Writedowns and Impairment readings, the most recent being -$232000.0 for Q2 2013.

On a quarterly basis, Asset Writedowns and Impairment changed N/A to -$232000.0 in Q2 2013 year-over-year; TTM through Jun 2016 was -$232000.0, a N/A change, with the full-year FY2022 number at $2.2 million, changed N/A from a year prior.
Asset Writedowns and Impairment hit -$232000.0 in Q2 2013 for Lifevantage, down from -$21000.0 in the prior quarter.
In the past five years, Asset Writedowns and Impairment ranged from a high of -$21000.0 in Q1 2013 to a low of -$232000.0 in Q2 2013.